Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 llow- and middle-income countries (LMICs), with first supplies due by the end of 2026.
|Articles|March 28, 2020
Recalls That Should Be on Your Radar—Week of March 22, 2020
Author(s)Contagion® Editorial Staff
We’ve compiled a list of recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week:
Advertisement
We’ve compiled a list of recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week:
Guan’s Mushroom Co Issues Recall of Enoki Mushrooms Due to Listeria monocytogenes Contamination
Guan’s Mushroom Co has issued a recall of all cases of its 200g/7.05 ounce packages of Enoki Mushroom due to the potential to be contaminated with Listeria monocytogenes.
Listeria monocytogenes can cause serious, even deadly, infections in older adults, the immunocompromised, and young children. In healthy individuals, there are typically only short term symptoms like fever, severe headache, nausea, stiffness, diarrhea, and abdominal pain.
No adverse health events have been reported to date in connection with this problem.
The potential for contamination was noted during routine testing by State of California.
The products affected are enoki mushrooms from South Korea. The FDA began investigating an
Read the
Dr. Reddy's Laboratories Issues Recall of Phytonadione Injectable Emulsion USP, 10 mg/mL Single-Dose Ampules Due To Ampules Breaking And Shattering Upon Opening
Dr. Reddy’s Laboratories Ltd. has issued a voluntary recall of 4 lots (ACB902, ACB903, ACB904, ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL, Single-Dose Ampules to the hospital level. The recall is due to product complaints received about ampules breaking and shattering, upon opening, during compounding.
The firm has received reports of cuts in skin and lacerations to health care professionals. There is a possibility of flying glass resulting in either temporary or permanent injury.
Phytonadione injectable emulsion is indicated in coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by Vitamin K deficiency or interference with Vitamin K activity.
Read the
Advertisement
Related to this article
David Altarac, MD, discusses 2025 SENTRY data, ESBL considerations in empiric therapy, and where ceftobiprole fits alongside ceftaroline in S aureus bacteremia.
A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Washington State Reports First US Avian Influenza Death of 2026
3
FDA Tentatively Approves First Generic Lenacapavir PrEP for 120 LMICs
4
Postapproval Surveillance Confirms Ceftobiprole Activity Against MRSA
5